NDA 017788 · Mylan Institutional
Rimso-50
Dimethyl Sulfoxide · Intravesical
NovelLast checked: Nov 20, 2026Latest source record: Aug 27, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1978
Apr 4, 1978
Approved uses
1
Original approval plus efficacy supplements
Registered trials
69
12 Phase 3, 7 recruiting
FAERS reports
243
198 serious, 31 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 17, 2021.
INDICATIONS AND USAGE RIMSO-50 ® (dimethyl sulfoxide) is indicated for the symptomatic relief of patients with interstitial cystitis. RIMSO-50 ® has not been approved as being safe and effective for any other indication. There is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial infections of the urinary tract.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 4, 1978 Original approval · Type 1 - New Molecular Entity
1 products under this application
- RIMSO-50 · DIMETHYL SULFOXIDE 50% · SOLUTION, INTRAVESICAL · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Dimethyl Sulfoxide" as an intervention, any sponsor and status, largest first.
- Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic SyndromePivotal-lookingCompleted
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoAcademic, hospital or other
NCT02960711 · 1,600 participants · Start Feb 2014 · Primary completion Jul 2019
Drug: Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]; Ludipress, mg stereate, micronized hydrated silica, talcum · For: Metabolic Syndrome
Sites: Milan, Italy
- Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line ChemotherapyPivotal-lookingCompleted
NovaRx CorporationIndustry
NCT00676507 · 532 participants · Start Jul 2008 · Primary completion Jan 2013
Drug: Lucanix™ · For: Lung Neoplasm; Carcinoma Non-small Cell Lung Cancer Stage IIIA; Carcinoma Non-small Cell Lung Cancer Stage IIIB and 1 more
Sites: Mobile, Alabama; Anchorage, Alaska; Scottsdale, Arizona · 82 sites in all
- Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has SpreadPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT02196181 · 280 participants (planned) · Start Sep 19, 2014 · Primary completion Mar 15, 2027
Drug: Dabrafenib Mesylate; Trametinib Dimethyl Sulfoxide · For: Stage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 752 sites in all
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT02224781 · 267 participants · Start Sep 8, 2015 · Primary completion Sep 30, 2023
Drug: Dabrafenib Mesylate; Ipilimumab and 2 more · For: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma and 2 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 838 sites in all
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02101788 · 260 participants · Start Apr 11, 2014 · Primary completion Apr 4, 2019
Drug: Letrozole; Paclitaxel and 4 more · For: Borderline Ovarian Serous Tumor; Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma and 3 more
Sites: Huntsville, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 501 sites in all
- Implantation Enhancement by Elective Cryopreservation of All Viable EmbryosPivotal-lookingCompleted
Universitair Ziekenhuis BrusselAcademic, hospital or other
NCT02148393 · 212 participants · Start May 2014 · Primary completion Feb 28, 2017
Drug: Pregnyl®; Utrogestan® and 1 more · For: Infertility; OHSS
Sites: Brussels, Belgium
Novartis PharmaceuticalsNovartis (NVS)
NCT01336634 · 177 participants · Start Aug 5, 2011 · Primary completion Oct 1, 2015
Drug: Dabrafenib; Trametinib · For: Cancer
Sites: Los Angeles, California; Orange, California; Aurora, Colorado · 50 sites in all
- DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)Pivotal-lookingCompleted
Cellphire Therapeutics, Inc.Industry
NCT04709705 · 161 participants · Start Oct 27, 2021 · Primary completion May 8, 2025
Drug: Human platelets · For: Cardiac Surgery
Sites: Birmingham, Alabama; Aurora, Colorado; Washington D.C., District of Columbia · 16 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective49
- headache48
- nausea48
- off label use42
- abdominal pain41
- pain39
- pyrexia39
- dyspepsia28
- fatigue28
- constipation27
- infusion related reaction27
- malaise27
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 6 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 5 |
| 2009 | 12 |
| 2010 | 4 |
| 2011 | 10 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 15 |
| 2016 | 4 |
| 2017 | 19 |
| 2018 | 14 |
| 2019 | 21 |
| 2020 | 16 |
| 2021 | 18 |
| 2022 | 21 |
| 2023 | 28 |
| 2024 | 10 |
| 2025 | 15 |
| 2026 | 10 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rimso-50 (Dimethyl Sulfoxide)
2024 spending
$568K
Beneficiaries
105
349 claims
Per beneficiary
$5,410
$13.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $646,201 |
| 2021 | $712,159 |
| 2022 | $583,889 |
| 2023 | $590,539 |
| 2024 | $568,071 |
Part B: Rimso-50 (Dimethyl Sulfoxide) · HCPCS J1212
2024 spending
$3.7M
Beneficiaries
701
5,614 claims
Per beneficiary
$5,260
2024 ASP limit $695.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,865,516 |
| 2021 | $3,916,042 |
| 2022 | $3,630,550 |
| 2023 | $3,361,204 |
| 2024 | $3,687,484 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Primary Localized Cutaneous Amyloidosis: A Systematic Treatment Review.
Weidner T, Illing T, Elsner P · Am J Clin Dermatol 2017 · Systematic Review
- Topical nonsteroidal anti-inflammatory drugs in the treatment of knee osteoarthritis: a systematic review and meta-analysis.
Wolff DG, Christophersen C, Brown SM, et al. · Phys Sportsmed 2021 · Meta-Analysis, Systematic Review
- Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder.
Tyagi P, Kashyap M, Yoshimura N, et al. · J Urol 2017 · Research Support, Non-U.S. Gov't, Systematic Review
- Impact of lower concentrations of dimethyl sulfoxide on cryopreservation of autologous hematopoietic stem cells: a systematic review and meta-analysis of controlled clinical studies.
Bennett B, Hanotaux J, Pasala AR, et al. · Cytotherapy 2024 · Systematic Review, Meta-Analysis
- The Development of an In Vitro Assay for the Prospective Determination of Aspirin Sensitivity.
Westphal ES, Wisniewski C, Rainka M, et al. · J Clin Pharmacol 2018 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Hematopoietic cell infusion-related adverse events in pediatric/small recipients in a prospective/multicenter study.
Ikeda K, Ohto H, Yamada-Fujiwara M, et al. · Transfusion 2020 · Clinical Trial, Multicenter Study
Sponsor: Mylan Institutional
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.